The HIV+Hepatitis Policy Institute strongly supports The PBM Accountability Study Act (HR 1829), which would require the Government Accountability Office to provide a comprehensive report to Congress on the ways in which PBMs influence the pricing of pharmaceuticals, impede competition, use rebates and also provide recommendations on ways to lower prescription drug costs.
Letter to Secretary Becerra about Policies & Solutions to Improve Prescription Drug Affordability for Patients
We, the undersigned 124 organizations, on behalf of millions of patients and American consumers who live with complex conditions such as HIV, autoimmune diseases, cancer, diabetes, lupus, multiple sclerosis, and hepatitis, write to congratulate you on becoming Secretary and express our deep commitment and interest in working with you, the Department of Health and Human Services (HHS), and the Biden administration to implement policies and measures that improve prescription drug affordability and access for the American people.
Support of Maryland House Bill 167 so that patients can afford their prescription medications
Comments on additional policy and regulatory revisions in response to the COVID-19 public health emergency
The HIV+Hepatitis Policy Institute, a national, non-profit organization whose mission is to promote quality and affordable healthcare for people living with or at risk of HIV, hepatitis, and other serious…
Comments on notice of benefit and payment parameters proposed for 2022 rule: CMS 9914-P
The HIV+Hepatitis Policy Institute, a national, non-profit organization whose mission is to promote quality and affordable healthcare for people living with or at risk of HIV, hepatitis, and other serious and chronic health conditions, is pleased to submit comments on the proposed Notice of Benefit and…